CASI Pharmaceuticals (CASI) has released an update.
CASI Pharmaceuticals has announced a $15 million private placement financing led by prominent investors, aiming to advance its development of innovative therapeutics. The financing involves the sale of 1,020,000 ordinary shares and pre-funded warrants, underlining investor confidence in the company’s strategic direction and mission. The deal, which is set to close in mid-July 2024, highlights CASI’s commitment to becoming a leader in the pharmaceutical industry, particularly in the hematology oncology sector.
For further insights into CASI stock, check out TipRanks’ Stock Analysis page.
